dallas glp-1 lawsuit Ozempic® GLP-1 Lawsuit | Stomach Paralysis,

Monitoring and follow-up: Regular follow-up during the first 3-6 months of therapy allows for symptom assessment, dose optimization, and early identification of complications

14,38,39 Several therapies currently in clinical development target glucagon receptors in addition to incretin receptors due to the effects of glucagon on reducing food intake and increasing energy expenditure

The most common side effectsnausea, diarrhea, constipation, and abdominal painare generally mild to moderate and improve with continued treatment

Therefore, the emergence of GLP-1 drugs opens new frontiers in weight management and diabetes care for patients in China, bringing hope for easier access and greater efficacy in treatments

Coverage depends on the specific medication and prescribing guidelines

Some autoinjectors do not require pinching, while pen devices may need a 1-2 inch skin fold